helicobacter pylori infection
Conditions
Interventions
Experimental Group:Capsule sampling line combined with qPCR technology was used to detect HP drug resistance genes. According to the drug sensitivity test results, two antibiotics were selected, and a
Control group:Empirical four-drug combination therapy for HP eradication (2 antibiotics, 1 PPI, and 1 bismuth)
Sponsors
The Third People's Hospital of Zhengzhou
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age range from 18 to 70 years old, regardless of gender. 2.Diagnosed as HP positive through breath test/gastric mucosal tissue pathology/rapid urease test. 3.Individuals with clear indications for HP eradication and voluntarily receiving initial treatment. 4.Volunteers accepting the string test. 5.Willing to use contraceptive measures during the research period. 6.Understand this study and voluntarily sign an informed consent form
Exclusion criteria
Exclusion criteria: 1.Allergic to the string test. 2.Within the past 4 weeks, have taken antibiotics, bismuth agents, traditional Chinese medicine with antibacterial effects, or proton pump inhibitors, potassium ion acid blockers, H2 receptor antagonists, and other drugs within 2 weeks. 3.With a history of major surgeries in the throat and upper gastrointestinal tract, including but not limited to Pilot I, Pilot II, total gastrectomy etc. 4.Suffering from malignant tumor of digestive tract within the past 5 years. 5.Minimally invasive surgery under gastroscopy in the past 4 weeks. 6.Taking adrenal cortex hormones, nonsteroidal anti-inflammatory drugs, and anticoagulants within the past 8 weeks. 7.Upper gastrointestinal bleeding within the past week. 8.Received clinical trials of other drugs or devices within the past 4 weeks. 9.There may be diseases or clinical conditions that may interfere with the evaluation of research and treatment, such as gastric or duodenal ulcers, liver diseases, cardiovascular diseases, lung diseases, kidney diseases, metabolic diseases. 10.With severe neurological or psychiatric disorders who are unable to cooperate with the examination. 11.Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance of precision medicine for HP eradication;String- test to detect HP and safety during medication (incidence of adverse events and adverse reactions);The resistance rate of HP to different antibiotics; | — |
Countries
China
Contacts
Public ContactYiCui
The third people's hospital of Zhengzhou
Outcome results
None listed